2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
Abstract
Flutter and Macroreentrant Atrial Tachycardia . . . . . . . . . . . . . . . .e206 2.2.Mechanisms of AF and Pathophysiology . . . . . .e207 2.2.1.Atrial Structural Abnormalities . . . . . . . .e207 2.2.2.Electrophysiological Mechanisms . . . . . .e208 2.2.2.1.Triggers of AF . . . . . . . . . . . . . .e208 2.2.2.2.Maintenance of AF. . . . .
Read the paper
Related studies
- Photochemical behavior of levofloxacin
- Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges
- Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes
- Synthesis of [11C]levofloxacin
- Fabrication, characterization, and docking studies of furosemide-loaded nanosponges using the emulsion solvent diffusion method
- The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.